Key result
Lead aVR elevation ≥1mm during exercise stress electrocardiography predicted early revascularization but did not significantly increase the risk of long-term cardiac events (HR 0.62).
Why the study?
ST elevation in lead aVR had not been studied for predicting ischemia, early revascularization, and subsequent cardiac events in the general population undergoing stress testing for initial CAD evaluation.
Does ST elevation ≥1mm in lead aVR during exercise stress electrocardiography predict ischemia, early revascularization, and long-term cardiac events in patients evaluated for CAD?
Cohort (n=641)
No
Does ST elevation ≥1mm in lead aVR during exercise stress electrocardiography predict ischemia, early revascularization, and long-term cardiac events in patients evaluated for CAD?
ST elevation ≥1mm in lead aVR during exercise stress testing strongly predicts ischemia and the need for early revascularization, though it does not predict long-term adverse cardiac events.
Answers are grounded in this paper and cite their sources.
aVR elevation may prompt early revascularization consideration; leaves open its role in long-term risk stratification.
BACKGROUND: Exercise stress electrocardiography (ExECG) is recommended as a first-line tool to assess ischemia, but standard ST-analysis has limited diagnostic accuracy. ST elevation in lead aVR has been associated with left main and LAD disease in the population undergoing coronary angiography but has not been studied in the general population undergoing stress testing for the initial evaluation of CAD without coronary angiography. We sought to determine the predictive value of lead aVR elevation for ischemia, early revascularization, and subsequent cardiac events in consecutive patients undergoing ExECG. METHODS AND RESULTS: The study cohort included 641 subjects referred for ExECG who were dichotomized by presence or absence of aVR elevation ≥1mm and compared for prevalence and predictors of ischemia and a composite of cardiac death, nonfatal myocardial infarction, and late revascularization. The cohort had a median age of 57 and 57% were male. The prevalence of aVR elevation was 11.5%. The prevalence of significant ischemia on patients who received imaging was significantly higher with aVR elevation (14.3% vs 2.3%, p<0.001). Early revascularization occurred in 10.9% with vs 0.2% without aVR elevation, p<0.001. No subjects without aVR elevation or ST-depression underwent early revascularization. However, cardiac event rates were similar over a median 4.0 years of follow-up with and without aVR elevation (2.8% vs. 2.6%, p = 0.80). aVR elevation did not predict long-term cardiac events by Kaplan-Meier survival analysis (p = 0.94) or Cox proportional hazards modeling (p = 0.35). CONCLUSIONS: aVR elevation during ExECG predicts ischemia on imaging and early revascularization but not long-term outcomes and could serve as a useful adjunct to standard ST-analysis and potentially reduce the need for concurrent imaging.
No takes yet. Share an insight, caveat, or question.
Baheti et al. (2021) conducted a cohort in Suspected coronary artery disease (n=641). Lead aVR elevation ≥1mm vs. No lead aVR elevation ≥1mm was evaluated on Composite of cardiac death, nonfatal myocardial infarction, and late revascularization (HR 0.62, 95% CI 0.22-1.70, p=0.35). Lead aVR elevation ≥1mm during exercise stress electrocardiography predicted early revascularization but did not significantly increase the risk of long-term cardiac events (HR 0.62).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: